COVID-19 'Pandemic'

Twin_Moose

Hall of Fame Member
Apr 17, 2017
18,113
3,938
113
Twin Moose Creek
Merck pill breakthrough raises hopes of preventing COVID deaths
Author of the article:Reuters
Reuters
Deena Beasley and Carl O'Donnell
Publishing date:Oct 01, 2021 • 12 hours ago • 4 minute read • 6 Comments
An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc on May 17, 2021.
An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc on May 17, 2021. PHOTO BY MERCK & CO INC / HANDOUT /REUTERS
Article content
An experimental antiviral pill developed by Merck & Co could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, according to data that experts hailed as a potential breakthrough in how the virus is treated.

Advertisement
STORY CONTINUES BELOW

Article content
If it gets authorization, molnupiravir, which is designed to introduce errors into the genetic code of the virus, would be the first oral antiviral medication for COVID-19.


Merck and partner Ridgeback Biotherapeutics said they plan to seek U.S. emergency use authorization for the pill as soon as possible and to make regulatory applications worldwide.

“An oral antiviral that can impact hospitalization risk to such a degree would be game-changing,” said Amesh Adalja, senior scholar at the Johns Hopkins Center for Health Security.

Current treatment options include Gilead Sciences Inc’s infused antiviral remdesivir and generic steroid dexamethasone, both of which are generally only given once a patient has already been hospitalized.

Advertisement
STORY CONTINUES BELOW

Article content
“This is going to change the dialog around how to manage COVID-19,” Merck Chief Executive Robert Davis told Reuters.

Existing treatments are “cumbersome and logistically challenging to administer. A simple oral pill would be the opposite of that,” Adalja added.


The results from the Phase III trial, which sent Merck shares up more than 9%, were so strong that the study is being stopped early at the recommendation of outside monitors.

Shares of Atea Pharmaceuticals Inc, which is developing a similar COVID-19 treatment, were up more than 21% on the news.

Shares of COVID-19 vaccine makers Moderna Inc were off more than 10%, while Pfizer was down less than 1%.

Jefferies analyst Michael Yee said investors believe “people will be less afraid of COVID and less inclined to get vaccines if there is a simple pill that can treat COVID.”

Advertisement
STORY CONTINUES BELOW

Article content
Pfizer and Swiss drugmaker Roche Holding AG are also racing to develop an easy-to-administer antiviral pill for COVID-19. For now, only antibody cocktails that have to be given intravenously are approved for non-hospitalized patients.


White House COVID-19 response coordinator Jeff Zients said on Friday that molnupiravir is “a potential additional tool… to protect people from the worst outcomes of COVID,” but added that vaccination “remains far and away, our best tool against COVID-19.”

A planned interim analysis of 775 patients in Merck’s study looked at hospitalizations or deaths among people at risk for severe disease. It found that 7.3% of those given molnupiravir twice a day for five days were hospitalized and none had died by 29 days after treatment. That compared with a hospitalization rate of 14.1% for placebo patients. There were also eight deaths in the placebo group.

Advertisement
STORY CONTINUES BELOW

Article content
“Antiviral treatments that can be taken at home to keep people with COVID-19 out of the hospital are critically needed,” Wendy Holman, Ridgeback’s CEO, said in a statement.

‘A HUGE ADVANCE’

Scientists welcomed the potential new treatment to help prevent serious illness from the virus, which has killed almost 5 million people around the world, 700,000 of them in the United States.

“A safe, affordable, and effective oral antiviral would be a huge advance in the fight against COVID,” said Peter Horby, a professor of emerging infectious diseases at the University of Oxford.


The study enrolled patients with laboratory-confirmed mild-to-moderate COVID-19, who had symptoms for no more than five days. All patients had at least one risk factor associated with poor disease outcome, such as obesity or older age.

Advertisement
STORY CONTINUES BELOW

Article content
Drugs in the same class as molnupiravir have been linked to birth defects in animal studies. Merck has said similar studies of molnupiravir – for longer and at higher doses than used in humans – indicate that the drug does not affect mammalian DNA.

Merck said viral sequencing done so far shows molnupiravir is effective against all variants of the coronavirus including the highly transmissible Delta, which has driven the recent worldwide surge in hospitalizations and deaths.

It said rates of adverse events were similar for both molnupiravir and placebo patients, but did not give details.

Merck has said data shows molnupiravir is not capable of inducing genetic changes in human cells, but men enrolled in its trials had to abstain from heterosexual intercourse or agree to use contraception. Women of child-bearing age in the study could be pregnant and also had to use birth control.

Advertisement
STORY CONTINUES BELOW

Article content

The U.S. drugmaker said it expects to produce 10 million courses of the treatment by the end of 2021.

The company has a U.S. government contract to supply 1.7 million courses of molnupiravir at a price of $700 per course.

Davis said Merck has similar agreements with other governments, and is in talks with more. Merck said it plans a tiered pricing approach based on country income criteria.

The U.S. government has the option to purchase up to an additional 3.5 million treatment courses if needed, a U.S. health official told Reuters. The official asked to remain anonymous because they were not authorized to comment publicly on the contract.

Merck has also agreed to license the drug to several India-based generic drugmakers, which would be able to supply the treatment to low- and middle-income countries.

Molnupiravir is also being studied in a Phase III trial for preventing infection in people exposed to the coronavirus.

Merck officials said it is unclear how long the FDA review will take, although Dean Li, head of Merck’s research labs, said, “they are going to try to work with alacrity on this.”'
I wonder what that drug costs compared to Ivermectin and HCQ

Watch: Dr. Campbell Reveals the Reason Behind India’s Ivermectin Blackout​

By Jim Hoft
Published October 3, 2021 at 7:45am
221 Comments

Dr. John Campbell broke India’s Ivermectin Blackout wide open on YouTube by revealing the formula of the secret sauce, much to the dismay of Big Pharma, the WHO, and the CDC. Readers will want to watch this before it is taken down. See mark 2:22.

Each home kit contained the following: Paracetamol tablets [tylenol], Vitamin C, Multivitamin, Zinc, Vitamin D3, Ivermectin 12 mg [quantity #10 tablets], Doxycycline 100 mg [quantity #10 tablets]. Other non-medication components included face masks, sanitizer, gloves and alcohol wipes, a digital thermometer, and a pulse oximeter. See mark 2:33.

Campbell reports that the exciting things in the kit that grabbed his attention were: Zinc, Vitamin D3, Ivermectin, and secondary antibiotic treatment. “Interesting, that’s what the government decided to give.” See mark 3:40.

He has reviewed repurposed drugs for COVID before. He has interviewed both Dr. Tess Lawrie and Dr. Pierre Kory. Repurposed drugs hold the potential for benefitting many conditions, not the least of which include viruses and cancers.
-
-
-
-
He attributes their success to many factors, including early detection and early treatment with kits costing a mere $ 2.65 per person. See mark 6:20.

Notice that Dr. Campbell does not mention a single person who had any toxicity from those ten 12 mg pills of Ivermectin – in the entire state of over 200 million. Not one poisoning was reported. No Indian poison control articles or telephone calls were reported. Out of millions of distributed medicine kits, each containing 120 mg of Ivermectin, not one person in Uttar Pradesh was reported to have had a problem with the drug.

Notice that Dr. Campbell at no time criticizes the medicine kit as “fringe” or ineffective. After all, it would be improper to accuse a WHO-sponsored program such as the Uttar Pradesh test and treat – coordinated by WHO – of being “fringe.”

Contrary to what little we receive – at great expense – from the government in the United States, these kits are efficient and contain gloves, a thermometer, and an oximeter. The last time I purchased an oximeter some ten years ago, it cost some $200.00. This entire kit – including the oximeter – costs only $2.65.

 

pgs

Hall of Fame Member
Nov 29, 2008
21,807
2,844
113
B.C.
Merck pill breakthrough raises hopes of preventing COVID deaths
Author of the article:Reuters
Reuters
Deena Beasley and Carl O'Donnell
Publishing date:Oct 01, 2021 • 12 hours ago • 4 minute read • 6 Comments
An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc on May 17, 2021.
An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc on May 17, 2021. PHOTO BY MERCK & CO INC / HANDOUT /REUTERS
Article content
An experimental antiviral pill developed by Merck & Co could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, according to data that experts hailed as a potential breakthrough in how the virus is treated.

Advertisement
STORY CONTINUES BELOW

Article content
If it gets authorization, molnupiravir, which is designed to introduce errors into the genetic code of the virus, would be the first oral antiviral medication for COVID-19.


Merck and partner Ridgeback Biotherapeutics said they plan to seek U.S. emergency use authorization for the pill as soon as possible and to make regulatory applications worldwide.

“An oral antiviral that can impact hospitalization risk to such a degree would be game-changing,” said Amesh Adalja, senior scholar at the Johns Hopkins Center for Health Security.

Current treatment options include Gilead Sciences Inc’s infused antiviral remdesivir and generic steroid dexamethasone, both of which are generally only given once a patient has already been hospitalized.

Advertisement
STORY CONTINUES BELOW

Article content
“This is going to change the dialog around how to manage COVID-19,” Merck Chief Executive Robert Davis told Reuters.

Existing treatments are “cumbersome and logistically challenging to administer. A simple oral pill would be the opposite of that,” Adalja added.


The results from the Phase III trial, which sent Merck shares up more than 9%, were so strong that the study is being stopped early at the recommendation of outside monitors.

Shares of Atea Pharmaceuticals Inc, which is developing a similar COVID-19 treatment, were up more than 21% on the news.

Shares of COVID-19 vaccine makers Moderna Inc were off more than 10%, while Pfizer was down less than 1%.

Jefferies analyst Michael Yee said investors believe “people will be less afraid of COVID and less inclined to get vaccines if there is a simple pill that can treat COVID.”

Advertisement
STORY CONTINUES BELOW

Article content
Pfizer and Swiss drugmaker Roche Holding AG are also racing to develop an easy-to-administer antiviral pill for COVID-19. For now, only antibody cocktails that have to be given intravenously are approved for non-hospitalized patients.


White House COVID-19 response coordinator Jeff Zients said on Friday that molnupiravir is “a potential additional tool… to protect people from the worst outcomes of COVID,” but added that vaccination “remains far and away, our best tool against COVID-19.”

A planned interim analysis of 775 patients in Merck’s study looked at hospitalizations or deaths among people at risk for severe disease. It found that 7.3% of those given molnupiravir twice a day for five days were hospitalized and none had died by 29 days after treatment. That compared with a hospitalization rate of 14.1% for placebo patients. There were also eight deaths in the placebo group.

Advertisement
STORY CONTINUES BELOW

Article content
“Antiviral treatments that can be taken at home to keep people with COVID-19 out of the hospital are critically needed,” Wendy Holman, Ridgeback’s CEO, said in a statement.

‘A HUGE ADVANCE’

Scientists welcomed the potential new treatment to help prevent serious illness from the virus, which has killed almost 5 million people around the world, 700,000 of them in the United States.

“A safe, affordable, and effective oral antiviral would be a huge advance in the fight against COVID,” said Peter Horby, a professor of emerging infectious diseases at the University of Oxford.


The study enrolled patients with laboratory-confirmed mild-to-moderate COVID-19, who had symptoms for no more than five days. All patients had at least one risk factor associated with poor disease outcome, such as obesity or older age.

Advertisement
STORY CONTINUES BELOW

Article content
Drugs in the same class as molnupiravir have been linked to birth defects in animal studies. Merck has said similar studies of molnupiravir – for longer and at higher doses than used in humans – indicate that the drug does not affect mammalian DNA.

Merck said viral sequencing done so far shows molnupiravir is effective against all variants of the coronavirus including the highly transmissible Delta, which has driven the recent worldwide surge in hospitalizations and deaths.

It said rates of adverse events were similar for both molnupiravir and placebo patients, but did not give details.

Merck has said data shows molnupiravir is not capable of inducing genetic changes in human cells, but men enrolled in its trials had to abstain from heterosexual intercourse or agree to use contraception. Women of child-bearing age in the study could be pregnant and also had to use birth control.

Advertisement
STORY CONTINUES BELOW

Article content

The U.S. drugmaker said it expects to produce 10 million courses of the treatment by the end of 2021.

The company has a U.S. government contract to supply 1.7 million courses of molnupiravir at a price of $700 per course.

Davis said Merck has similar agreements with other governments, and is in talks with more. Merck said it plans a tiered pricing approach based on country income criteria.

The U.S. government has the option to purchase up to an additional 3.5 million treatment courses if needed, a U.S. health official told Reuters. The official asked to remain anonymous because they were not authorized to comment publicly on the contract.

Merck has also agreed to license the drug to several India-based generic drugmakers, which would be able to supply the treatment to low- and middle-income countries.

Molnupiravir is also being studied in a Phase III trial for preventing infection in people exposed to the coronavirus.

Merck officials said it is unclear how long the FDA review will take, although Dean Li, head of Merck’s research labs, said, “they are going to try to work with alacrity on this.”'
Ivermectin .
 
  • Like
Reactions: Twin_Moose

spaminator

Hall of Fame Member
Oct 26, 2009
29,223
1,289
113
Unvaxxed Ontario MPP Rick Nicholls steps down from deputy speaker role
He said he believes people shouldn't be penalized over a vaccination choice

Author of the article:Antonella Artuso
Publishing date:Oct 05, 2021 • 15 hours ago • 1 minute read • 74 Comments
Ontario MPP Rick Nicholls holds a news conference at Queen's Park in Toronto on Thursday, August 19, 2021, to announce that he would not get vaccinated against COVID-19.
Ontario MPP Rick Nicholls holds a news conference at Queen's Park in Toronto on Thursday, August 19, 2021, to announce that he would not get vaccinated against COVID-19. PHOTO BY CHRIS YOUNG /THE CANADIAN PRESS
Article content
Independent MPP Rick Nicholls is stepping down as deputy speaker of the Ontario legislature after the government indicated it planned to replace him.

Advertisement
STORY CONTINUES BELOW

Article content
Premier Doug Ford ousted Nicholls from the Progressive Conservative caucus after he refused to provide proof of COVID-19 vaccination or a medical exemption.


The government announced Monday it would introduce a motion to remove Nicholls from his deputy speaker position and replace him with Tory MPP Bill Walker,

“Serving the people of the Ontario Legislative Assembly and the people of Ontario in this capacity has been very rewarding and, yes, even challenging at times,” Nicholls said Tuesday, of his positions as deputy speaker and chair of the Committee of the Whole House. “Knowing how to respond to tense situations takes a certain skillset to respectfully calm the waters, and I was able to do that successfully.

Advertisement
STORY CONTINUES BELOW

Article content
“However, the government attempted to force me into getting the vaccine or be removed from caucus. Sticking to my values and my principles, I refused to get the vaccine so the government made good on their threat by removing me from caucus and prohibiting me from running in the 2022 election as a PC candidate,” he said.


Nicholls said he made a personal decision to not be vaccinated but would not describe himself as anti-vaxxer and believes people shouldn’t be penalized over a vaccination choice.

The vast majority of eligible Ontarians have been vaccinated against COVID-19, and Ford has said that his MPPs must show leadership on this issue.

aartuso@postmedia.com
 

spaminator

Hall of Fame Member
Oct 26, 2009
29,223
1,289
113
College of Nurses investigating RNAO boss over social media post
Author of the article:Anthony Furey
Publishing date:Oct 05, 2021 • 14 hours ago • 2 minute read • 53 Comments
Doris Grinspun
Doris Grinspun PHOTO BY ANTONELLA ARTUSO /Toronto Sun
Article content
The College of Nurses of Ontario (CNO) is investigating Doris Grinspun, the CEO of the Registered Nurses’ Association of Ontario (RNAO), over controversial remarks made on social media, the Toronto Sun has learned.

The complaints concern a post Grinspun made on Twitter on Sept. 17 in response to a question posted by physician and CBC personality Brian Goldman, who asked what should be done if someone has a neighbour who has anti-vaccine signs on their property and lawn signs supporting the People’s Party of Canada.


Grinspun posted in response: “I bring them one of my yummy Empanadas and put a strong dose of dulcolax in!!!!”

This riled up many people on social media, who viewed the post as a nurse publicly threatening to hide drugs in people’s food.

Goldman’s post has since been deleted, but Grinspun’s remains.

Advertisement
STORY CONTINUES BELOW

Article content

The Sun was copied on many complaints sent to the CNO from members of the public. The bulk of the complaints were made of the same or similar text and appear to be part of a letter writing campaign.

“If this situation were reversed and an RN publicly recommended hiding harmful drugs in the food of a vaccine advocate, the CNO would surely respond with a swift and harsh penalty,” the complaint letter reads. “Since Doris Grinspun is in a position of influence, she needs to be held to an even higher standard.”


While Grinspun did not respond to a request for comment from the Sun, she did later post a follow-up note: “To my #antivaxxer friends, I do apologize for a poor taste joke. It was meant to call your attention and now that I have it let’s talk. Please know that I care for you deeply and am afraid some of you may end up hospitalized and perhaps even in ICU.”

When the CNO confirmed to the Sun that they were investigating the matter, they also sent an information page describing the investigation process and how it can ultimately conclude in a committee cautioning a nurse or requiring continuing education or remediation.
 

Twin_Moose

Hall of Fame Member
Apr 17, 2017
18,113
3,938
113
Twin Moose Creek

Without Lockdowns, Sweden Had Fewer Excess Deaths Than Most Of Europe​

BY TYLER DURDEN
WEDNESDAY, OCT 06, 2021 - 06:30 AM

Yet in 2020, led by health technocrats at the World Health Organization, nearly all national governments in the world suddenly and without precedent embraced the idea of lockdowns.

On the other hand, the Swedish regime rejected the idea.

For this act of iconoclasm, the Swedish government was pilloried by media organizations and non-Swedish government officials worldwide. The predictions of doom and of a widespread Swedish bloodbath were ubiquitous. Months later, even when it became clear Sweden was not the death-addled outlier many assumed it would be, it was common to see articles declaring Swedish covid policy to be a “disaster.”

Even eighteen months later, as the Sweden-is-doomed narrative broke down even more, critics of Sweden contort themselves to create an anti-Swedish narrative. Consider this August 2021 article at Business Insider, for example, which carefully slices and dices the data to make Sweden’s outcomes look bad. The author slyly writes:

Since the start of the pandemic, roughly 11 out of every 100 people in Sweden have been diagnosed with COVID-19, compared with 9.4 out of every 100 in the UK and 7.4 per 100 in Italy. Sweden has also recorded around 145 COVID-19 deaths for every 100,000 people — around three times more than Denmark, eight times more than Finland, and nearly 10 times more than Norway.
Note the sleight of hand used here. In one sentence, the comparison focuses on diagnoses compared to the UK and Italy. This is surely because actual deaths from covid are fewer per million in Sweden than in either of the UK or Italy. Indeed, the author with this comparison only succeeds in showing us that covid is less fatal in Sweden where there are more cases but fewer deaths. The author then quickly changes the subject to comparisons in deaths so as to make sure Sweden compares unfavorably to Denmark, Finland, and Norway.

These claims are becoming increasingly desperate, since in terms of excess deaths Sweden is better off than most of Europe overall, and also better off than most other northern European countries. (And much better than southern European countries.) Moreover, "excess mortality" is a better measure of deaths in a given country since it provides a broader view of the actual effects of both covid and covid policy.

Certainly, one can find some European regimes that had fewer deaths proportionally. Norway, Denmark, and Finland have remarkably low numbers of covid deaths compared to all of Europe.

But this fails to explain why Sweden’s non-bloodbath compares favorably to most EU member states, including France, Italy, Spain, the Netherlands, and others.

For example, as of late August, excess mortality in Sweden was approximately 785 per million people. In France, the total is 988 per million, and in Spain, it is 1,917 per million. In EU nonmember the United Kingdom, the total is 1,657 per million. ....More
 

spaminator

Hall of Fame Member
Oct 26, 2009
29,223
1,289
113
‘COVID toes’ caused by body attacking its own cells: Study
Author of the article:Denette Wilford
Publishing date:Oct 06, 2021 • 9 hours ago • 2 minute read • Join the conversation
'Covid toes', a skin manifestation and symptom of COVID-19, are visible on a COVID-19 patient being treated in the Intensive Care Unit (ICU) at Sharp Grossmont Hospital on December 14, 2020 in La Mesa, California.
'Covid toes', a skin manifestation and symptom of COVID-19, are visible on a COVID-19 patient being treated in the Intensive Care Unit (ICU) at Sharp Grossmont Hospital on December 14, 2020 in La Mesa, California. PHOTO BY MARIO TAMA /Getty Images
Article content
There’s a possible symptom people with COVID-19 have gotten that we aren’t really talking about: ‘COVID toes.’

Advertisement
STORY CONTINUES BELOW

Article content
Granted, that’s not the actual name but chilblains, a skin condition that affects toes and sometimes fingers where redness, swelling, or red or purple bumps or blisters can appear.


For some, it’s more of an aesthetic issue, while the rash can be sore and itchy for others.

Researchers believe it happens because the body mistakenly attacks its own cells, according to a study out of France.

“The epidemiology and clinical features of chilblain-like lesions have been extensively studied and published,” said Dr. Charles Cassius, one of the researchers from Paris’ Saint-Louis Hospital, in the British Journal of Dermatology. “However, little is known about the pathophysiology involved.”

MORE ON THIS TOPIC

A Walmart pharmacist holds a vial of the Moderna vaccine inside a department store in West Haven, Connecticut, February 17, 2021.
Sweden, Denmark pause use of Moderna COVID-19 vaccine for younger age groups
In this photo illustration, a man uses a COVID-19 rapid antigen test kit at home on Sept. 29, 2021 in Sydney, Australia.
Rapid tests coming to Ontario schools but not all of them
The most common of more than 200 different long COVID symptoms include fatigue, shortness of breath, general pain or discomfort, anxiety and depression.
Ontario has tens of thousands experiencing 'long COVID-19' symptoms: Science group

Advertisement
STORY CONTINUES BELOW

Article content
According to Cassius, their latest study “provides new insights.”

The doctors examined 50 patients with the dreaded ‘COVID toes,’ as well as 13 others who experienced chilblain-like lesions prior to the pandemic.

The study found patients in both groups had high amounts of two elements of the immune system: a protein called type 1 interferon and an antibody called anti-neutrophil cytoplasmic antibodies.

Both can attack a person’s healthy cells and tissues as the immune system goes into overdrive attempting to fight off the virus.

The lesions appeared on toes in 86% of the cases, and showed up on the fingers of 24% of those analyzed.

Experts believe infections in those with COVID toes are mild to otherwise asymptomatic because the body’s immune response has fired up.

Advertisement
STORY CONTINUES BELOW

Article content
“This study illustrates that both the immune system and endothelial cells play a critical role in the genesis of CLL (chilblain-like lesions),” the authors said.


Patients are advised to consult a dermatologist or physician to rule out other causes – which is what many people did when COVID toes first became a thing in the spring of 2020.

Dermatology practices were flooded with concerned people experiencing the chilblain-like lesions, specifically children and teenagers, as it was mostly young people reporting the sores.

The lesions usually go away on their own, though some patients require creams and medications.

The researchers also suggest that anti-inflammatory treatments could reverse the skin condition in COVID patients.

COVID toes have yet to be added to the official list of coronavirus symptoms in North America or the U.K., despite some experts suggesting their presence should be considered another reason for testing.
1633591218793.png
 

Twin_Moose

Hall of Fame Member
Apr 17, 2017
18,113
3,938
113
Twin Moose Creek

UPDATE: Merck Sells Its Federally Financed COVID Pill to US for 40 Times What It Costs to Produce​

By Jim Hoft
Published October 6, 2021 at 2:41pm
725 Comments

What a surprise!
The mainstream fake news media hailed the news last week that Merck Corporation had discovered a drug treatment for the COVID virus.

This comes over a year after the discovery that hydroxychloroquine was successful in treating the coronavirus in its early stages and months after it was discovered the Ivermectin had amazing success in treating the coronavirus, especially in India.

Merck is not just giving their new drug away. The company is charging the US government 40 times what it costs to produce their new wonder drug.

It’s another win for Big Pharma

The Intercept reported:

A FIVE-DAY COURSE of molnupiravir, the new medicine being hailed as a “huge advance” in the treatment of Covid-19, costs $17.74 to produce, according to a report issued last week by drug pricing experts at the Harvard School of Public Health and King’s College Hospital in London. Merck is charging the U.S. government $712 for the same amount of medicine, or 40 times the price.

Last Friday’s announcement that the new medicine cut the risk of hospitalization among clinical trial participants with moderate or mild illness in half could have huge implications for the course of the coronavirus pandemic. Because it’s a pill — as opposed to monoclonal antibodies, a comparable antiviral treatment that is administered intravenously — molnupiravir is expected to be more widely used and, hopefully, will cut the death rate. In the first 29 days of the trial, no deaths were reported among the 385 patients who received the drug, while eight of the people who received a placebo died, according to the statement put out by Merck and Ridgeback Biotherapeutics, the two companies that are jointly launching it.

In addition to having huge implications for health, the pill could bring staggering profits to both Merck and Ridgeback Biotherapeutics. A small Miami-based company, Ridgeback licensed the medicine from Emory University in 2020 and two months later sold the worldwide rights to the drug to Merck for an undisclosed sum. Although Ridgeback remains involved in the development of the drug, some have described the deal as “flipping.”
 

spaminator

Hall of Fame Member
Oct 26, 2009
29,223
1,289
113
Man allegedly killed pharmacist brother and two others over vaccine beliefs
Author of the article:Liz Braun
Publishing date:Oct 07, 2021 • 13 hours ago • 2 minute read • Join the conversation
Jeffrey Allen Burnham ofMaryland is accused of killing his pharmacist brother, his sister-in-law and an 83-year-old woman.
Jeffrey Allen Burnham ofMaryland is accused of killing his pharmacist brother, his sister-in-law and an 83-year-old woman. PHOTO BY (ALLEGANY COUNTY SHERIFF'S OFFICE/CNN) /TORONTO SUN
Article content
Mental illness appears to have played a role in a triple murder in Maryland last week.

Advertisement
STORY CONTINUES BELOW

Article content
A Cumberland man who expressed the delusion that the government is poisoning people with COVID 19 vaccines is accused of killing his brother — a pharmacist who administers the vaccines — and two others.


Jeffrey Burnham, 46, is alleged to have shot and killed his brother Brian Robinette, 58, and his sister in law, Kelly Sue Robinette, 57 as well as 83-year-old Rebecca Reynolds, a lifelong friend of the accused’s mother.

Police charging documents show that a day before the killing spree, Burnham had told his mother, Evelyn Burnham, 83, he was upset that his pharmacist brother was giving COVID vaccinations.

After Burnham’s arrest, his mother, in tears at her Cumberland, Maryland home, said to the Baltimore Sun of her son, “I just hope they find out what went wrong in his head.”

Advertisement
STORY CONTINUES BELOW

Article content
According to police, Jeffrey Burnham killed Rebecca Reynolds at her Fourth Street home in Cumberland on Sept. 29, stealing her car to drive to his brother’s house on Kerger Road in Ellicott City.

Burnham killed his brother and his brother’s wife and then stole their car and went on the run.

On the morning of Friday, Oct. 1, Burnham stopped a firefighter in West Virginia and told him he had been, “forced to kill three people.”

Police arrested him that morning after an 18-hour manhunt.

NBC News reported that Burnham is alleged to have taken his brother’s Corvette after the murders and stopped at someone’s home asking for gas. He told the person who answered the door that they’d see him on TV and that his brother was, “killing people with the Covid shot.”

Advertisement
STORY CONTINUES BELOW

Article content
That person called the state police.

It was later disclosed that Burnham’s mother was so concerned about his erratic behaviour and his mental health that she phoned police two days in a row — first on the day he killed her friend Reynolds, and a day later, which was the day Burnham allegedly killed his brother and his brother’s wife.

The Baltimore Sun reports that police charging documents do not specify whether her calls were made prior to the killings; they also do not specify what Cumberland police did in response to the calls.


Burnham is charged with two counts of first-degree murder and two counts of second-degree murder in the deaths. He has been ordered to remain in the Allegany County Detention Centre while awaiting trial.

A GoFundMe in honour of longtime Ellicott City residents Kelly and Brian Robinette, organized to help their two young adult children, has raised over $100,000 in 48 hours.
 

taxslave

Hall of Fame Member
Nov 25, 2008
34,279
2,808
113
Vancouver Island
I wonder what that drug costs compared to Ivermectin and HCQ

Watch: Dr. Campbell Reveals the Reason Behind India’s Ivermectin Blackout​

By Jim Hoft
Published October 3, 2021 at 7:45am
221 Comments

Dr. John Campbell broke India’s Ivermectin Blackout wide open on YouTube by revealing the formula of the secret sauce, much to the dismay of Big Pharma, the WHO, and the CDC. Readers will want to watch this before it is taken down. See mark 2:22.

Each home kit contained the following: Paracetamol tablets [tylenol], Vitamin C, Multivitamin, Zinc, Vitamin D3, Ivermectin 12 mg [quantity #10 tablets], Doxycycline 100 mg [quantity #10 tablets]. Other non-medication components included face masks, sanitizer, gloves and alcohol wipes, a digital thermometer, and a pulse oximeter. See mark 2:33.

Campbell reports that the exciting things in the kit that grabbed his attention were: Zinc, Vitamin D3, Ivermectin, and secondary antibiotic treatment. “Interesting, that’s what the government decided to give.” See mark 3:40.

He has reviewed repurposed drugs for COVID before. He has interviewed both Dr. Tess Lawrie and Dr. Pierre Kory. Repurposed drugs hold the potential for benefitting many conditions, not the least of which include viruses and cancers.
-
-
-
-
He attributes their success to many factors, including early detection and early treatment with kits costing a mere $ 2.65 per person. See mark 6:20.

Notice that Dr. Campbell does not mention a single person who had any toxicity from those ten 12 mg pills of Ivermectin – in the entire state of over 200 million. Not one poisoning was reported. No Indian poison control articles or telephone calls were reported. Out of millions of distributed medicine kits, each containing 120 mg of Ivermectin, not one person in Uttar Pradesh was reported to have had a problem with the drug.

Notice that Dr. Campbell at no time criticizes the medicine kit as “fringe” or ineffective. After all, it would be improper to accuse a WHO-sponsored program such as the Uttar Pradesh test and treat – coordinated by WHO – of being “fringe.”

Contrary to what little we receive – at great expense – from the government in the United States, these kits are efficient and contain gloves, a thermometer, and an oximeter. The last time I purchased an oximeter some ten years ago, it cost some $200.00. This entire kit – including the oximeter – costs only $2.65.

Not seeing the point of a pulsox. And where does one find a pulsox that cheap?
 
  • Like
Reactions: Twin_Moose